The Food and Drug Administration on Thursday granted accelerated approval to a new dual-acting drug from Amgen to treat small cell lung cancer in people whose disease has progressed following ...
Amgen’s Bkemv is the first interchangeable biosimilar to Soliris to treat certain rare diseases. The treatment of patients ...
The U.S. Food and Drug Administration approved on Tuesday Amgen's Bkemv, the first biosimilar to AstraZeneca's rare blood ...
(Reuters) -The U.S. Food and Drug Administration approved on Tuesday Amgen's Bkemv, the first biosimilar to AstraZeneca's rare blood disorder treatment Soliris. Amgen's drug will be marketed under ...
(Reuters) -The U.S. Food and Drug Administration approved on Tuesday Amgen’s Bkemv, the first biosimilar to AstraZeneca’s rare blood disorder treatment Soliris. Amgen’s drug will be marketed under the ...
The U.S. Food and Drug Administration on Thursday approved a new drug to treat patients with an advanced form of deadly lung cancer. The U.S. Food and Drug Administration on Thursday approved a new ...
Tarlatamab arrives after decades of no real treatment advances for this type of lung cancer. HealthDay News — The U.S. Food and Drug Administration on Thursday approved a new drug to treat ...